Education
About Us
Working with TipRanks
Follow Us
Heron Therapeutics Inc (HRTX)
:HRTX
HRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.04 - $3.93
Previous CloseN/A
Volume327.52K
Average Volume (3M)2.10M
Market Cap
$348.83M
Enterprise Value$411.49M
Total Cash (Recent Filing)$25.80M
Total Debt (Recent Filing)$177.76M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
May 12, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding152,329,590
10 Day Avg. Volume4,034,404
30 Day Avg. Volume2,104,396
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.34
Price to Cash Flow (P/CF)-7.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.90
Enterprise Value/Ebitda-73.00
Forecast
1Y Price Target
$6.50Price Target Upside183.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Heron Therapeutics News
PremiumCompany Announcements
Heron Therapeutics Reports Strong 2024 Financial Results
PremiumCompany Announcements
Heron Therapeutics Inc. Reports Strong Earnings and Strategic Growth
PremiumCompany Announcements
Heron Therapeutics Relocates Headquarters to North Carolina
---
Bulls Say, Bears Say
Bulls Say
Court DecisionThe court decision is a significant positive for HRTX that should eliminate the threat of a potential near-term generic Cinvanti launch.
Product DevelopmentFDA approved HRTX's application for a new product presentation of Zynrelef that includes a vial access needle (VAN).
Bears Say
Financial ChallengesThere is a financial overhang associated with the 2026 convertible notes, expected to be addressed in 2025.
---
Ownership Overview
5.26% Insiders
8.74% Mutual Funds
44.40% Other Institutional Investors
32.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HRTX FAQ
What was Heron Therapeutics Inc’s price range in the past 12 months?
Heron Therapeutics Inc lowest stock price was $1.04 and its highest was $3.93 in the past 12 months.
What is Heron Therapeutics Inc’s market cap?
Heron Therapeutics Inc’s market cap is $348.83M.
When is Heron Therapeutics Inc’s upcoming earnings report date?
Heron Therapeutics Inc’s upcoming earnings report date is May 12, 2025 which is in 60 days.
How were Heron Therapeutics Inc’s earnings last quarter?
Heron Therapeutics Inc released its earnings results on Feb 27, 2025. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.031 by $0.051.
Is Heron Therapeutics Inc overvalued?
According to Wall Street analysts Heron Therapeutics Inc’s price is currently Undervalued.
Does Heron Therapeutics Inc pay dividends?
Heron Therapeutics Inc does not currently pay dividends.
What is Heron Therapeutics Inc’s EPS estimate?
Heron Therapeutics Inc’s EPS estimate is -0.02.
How many shares outstanding does Heron Therapeutics Inc have?
Heron Therapeutics Inc has 152,329,590 shares outstanding.
What happened to Heron Therapeutics Inc’s price movement after its last earnings report?
Heron Therapeutics Inc reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.031. Following the earnings report the stock price went up 19.883%.
Which hedge fund is a major shareholder of Heron Therapeutics Inc?
Currently, no hedge funds are holding shares in HRTX
---
Heron Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (183.84% Upside)
$6.50 (183.84% Upside)
Blogger Sentiment
Bearish
HRTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 15.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.97%
12-Months-Change
Fundamentals
Return on Equity
40.36%
Trailing 12-Months
Asset Growth
4.78%
Trailing 12-Months
Company Description
Heron Therapeutics Inc
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
---
HRTX Company Deck
---
HRTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant achievements in profitability, revenue growth, and operational efficiency, alongside successful product developments and legal victories. However, challenges remain with increased competition, cash flow management, and ongoing legal and R&D expenses.Read More>---
HRTX Stock 12 Month Forecast
Average Price Target
$6.50
▲(183.84% Upside)
Technical Analysis
Best Analysts Covering HRTX
1 Year
1 Year Success Rate
8/31 ratings generated profit
1 Year Average Return
-23.60%
reiterated a buy rating 14 days ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 25.81% of your transactions generating a profit, with an average return of -23.60% per trade.
---